Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2198 SGI-1776 free base <1 mg/mL 81 mg/mL 81 mg/mL
S8005 SMI-4a <1 mg/mL 55 mg/mL 32 mg/mL
S8800 INCB053914 -1 mg/mL 50 mg/mL -1 mg/mL
S7985 PIM447 (LGH447) <1 mg/mL 88 mg/mL 88 mg/mL
S7104 AZD1208 <1 mg/mL 75 mg/mL <1 mg/mL
S7041 CX-6258 HCl 89 mg/mL 57 mg/mL 1 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations

SGI-1776 free base

SGI-1776 free base is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM in a cell-free assay, 50- and 10-fold selective versus Pim2 and Pim3, also potent to Flt3 and haspin. Phase 1.



SMI-4a is a potent inhibitor of Pim1 with IC50 of 17 nM, modestly potent to Pim-2, does not significantly inhibit any other serine/threonine- or tyrosine-kinases.



INCB053914 is a novel, ATP-competitive, small molecule, pan-inhibitor of PIM kinases with IC50 values of 0.24 nM, 30 nM and 0.12 nM for PIM1, PIM2 and PIM3 respectively in biochemical assays.


PIM447 (LGH447)

PIM447 is a novel pan-PIM kinase inhibitor with Ki values of 6 pM, 18 pM, 9 pM for PIM1, PIM2, PIM3 respectively. It also inhibits GSK3β, PKN1, and PKCτ, but at a significantly lower potency with IC50 between 1 and 5 μM (>105-fold differential relative to the Ki on PIMs).



AZD1208 is a potent, and orally available Pim kinase inhibitor with IC50 of 0.4 nM, 5 nM, and 1.9 nM for Pim1, Pim2, and Pim3 in cell-free assays, respectively. Phase 1.


CX-6258 HCl

CX-6258 HCl is a potent, orally efficacious pan-Pim kinase inhibitor with IC50 of 5 nM, 25 nM and 16 nM for Pim1, Pim2, and Pim3, respectively.